NVDA News
R40 coverage and dated third-party headlines for NVIDIA Corporation (NVDA).
R40 Coverage
In February We Warned That Beating Wouldn't Be Enough. Nvidia Beat, Then Grew Another 20%.
Nvidia beat the consensus our February preview named by 3.9% on revenue and 15.8% on EPS, then grew 20% again the quarter after. Half that call we can grade.
The AI Capex Bet, Six Months In: What the Mag 7 Actually Spent (and What the Market Learned)
Our February call was a $700B AI capex arms race. Six months and a full Q2 earnings season later, actual guidance has blown past that number, free cash flow is cratering at multiple hyperscalers, and the market has started rewarding capex very differently depending on who's spending it. Here's what changed.
Nvidia Reports Next Week. Wall Street Has Never Been This Confident.
Nvidia's Q4 FY2026 earnings drop February 25. Analysts expect $65.6B in revenue and $1.52 EPS — but the stock is flat in 2026. Here's what the numbers say and what could go wrong.
The $700B AI Bet: Inside the Mag 7's Record 2026 CapEx Arms Race
The Magnificent Seven are set to spend $700B+ on AI infrastructure in 2026, up 60% from 2025. We break down who's spending what, the supply chain winners, and why the market is spooked.
Prediction Markets
February 2026
Jensen Huang: Demand explosion easing GPU depreciation fears
Old GPUs increasing in price; hyperscaler capex acceleration benefits NVDA and neoclouds.
NVDA CEO on compute demand
OpenAI/Anthropic revenue could 4x with more compute; massive constraint driving spend.
Nvidia shares surge 7-8% leading tech rebound
Big Tech's $650B AI capex plans (incl. Amazon's $200B) drive gains; Jensen Huang highlights compute constraints and rising GPU values.
NVDA Short-Term Pressure
Reports of AI customers exploring alternatives and China H200 delays; dominates AI chips, bullish ratings ahead of earnings.
NVDA Rejection from Supply
Sharp rejection from 480–490; bounce from demand but rallies sellable; weak sell bias unless reclaim mid-450s.
January 2026
NVDA Not Finished
Structural selling; growth concerns and valuation compression continue downside.